New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
09:12 EDTARMH, BSX, FURX, ACH, EMR, ZNGA, PSMI, TTWO, PSEC, NUS, AEIS, JCP, ENTG, KORS, ATMIOn The Fly: Pre-market Movers
HIGHER: Michael Kors (KORS), up 21% after Q3 earnings beat expectations, company raises guidance... Furiex (FURX), up 124% after reporting top-line results for its Phase III trials evaluating its irritable bowel syndrome treatment... Zynga (ZNGA), up 7% following upgrade at UBS... J.C. Penney (JCP), up 3.5% after reporting positive Q4 comparable store sales... Nu Skin (NUS), up 2% after Q4 EPS and revenue view top expectations... ATMI (ATMI), up 25% after peer Entegris (ENTG) agrees to acquire company for $34.00 per share. Entegris shares also up 17% after deal announcement, while others in the sector, such as Advanced Energy Industries (AEIS) also rose... DOWN AFTER EARNINGS: ARM Holdings (ARMH), down 6.8%... Arch Coal (ACI), down 1.8%. ALSO LOWER: Take-Two (TTWO), down 6% after earnings report, downgrades at Wedbush and Benchmark... Peregrine (PSMI), down 16% after earnings, downgrades at Needham and JPMorgan.
News For KORS;JCP;ATMI;ENTG;AEIS;NUS;ZNGA;FURX;PSEC;EMR;BSX;TTWO;ACH;ARMH;PSMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 20, 2015
10:00 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:01 EDTJCPJ.C. Penney says general counsel Janet Dhillon to leave company
J.C. Penney said in a filing that effective March 20, Janet Dhillon, Executive Vice President, General Counsel and Secretary, is leaving J. C. Penney Company.
08:32 EDTBSXBoston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on March 27 at 11 am.
06:44 EDTBSXBoston Scientific initiated with an Outperform at Raymond James
Subscribe for More Information
March 18, 2015
13:30 EDTJCPJ.C. Penney trades lower after news of executive departures
Subscribe for More Information
10:48 EDTARMHCadence, ARM announce strategic IP interoperability agreement
Subscribe for More Information
10:06 EDTKORSMichael Kors recent headwinds provide a buying opportunity, says BofA/Merrill
Subscribe for More Information
06:25 EDTNUSCiti calls Nu Skin its 'pot of gold on St. Patrick’s Day'
Subscribe for More Information
05:39 EDTBSXSt. Jude Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded St. Jude Medical (STJ) to Market Perform saying competitive pressures will drive 2015 market share losses in the company's cardiac rhythm management business, which represents 50% of total sales. Wells believes the launch of CardioMEMS will not be strong enough to offset the headwinds in CRM unit. The firm thinks Boston Scientific's (BSX) earlier than expected approval for its next generation subcutaneous implantable cardioverter-defibrillator called Emblem will drive share gains against St. Jude and Medtronic (MDT) in the single chamber ICD market. Wells cut its price target range for St. Jude shares to $69-$70 from $73-$74. The medical technology company closed yesterday down $2.01 to $65.45.
March 17, 2015
16:13 EDTBSXBoston Scientific announces FDA, CE Mark approval of EMBLEM S-ICD system
Boston Scientific has received FDA and CE Mark approval of the EMBLEM Subcutaneous Implantable Defibrillator, or S-ICD, system. The EMBLEM S-ICD System is a treatment option that provides protection for patients at risk of sudden cardiac arrest, yet leaves the heart and vasculature untouched, minimizing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillators. A controlled and limited market release has begun in a small number of European centers with a broad European launch scheduled for May and subsequent U.S. launch planned for the third quarter of 2015.
15:41 EDTJCPJ.C. Penney General Counsel Janet Dhillon leaving, Bloomberg says
Subscribe for More Information
06:57 EDTJCPJ.C. Penney CMO leaves company, effective immediately, AdAge reports
Subscribe for More Information
March 16, 2015
17:08 EDTNUSNu Skin gets direct selling authorization for additional city in mainland China
Nu Skin Enterprises announced it has received approval from China's Ministry of Commerce for the company to commence direct selling activities in Shaoxing City in Zhejiang Province. Nu Skin is now licensed in 30 cities in 19 provinces and municipalities. The licensing process included a review of the company's operations. According to the Shaoxing City government, the city's population was more than 6M in 2013.
13:16 EDTBSXAnalysts upbeat on results of Edwards' Sapien 3 data
The shares of Edwards Lifesciences (EW) are rising after the company released data on its Sapien 3 transcathter aortic valve over the weekend. In notes to investors today, a number of analysts were upbeat on the data. BACKGROUND: Edwards yesterday announced that high- and intermediate-risk patients treated with Sapien 3 demonstrated lower mortality rates than patients treated with previous transcathter aortic valves, or TAVR, made by the company. The patients also had excellent clinical outcomes in the other primary endpoints of stroke and paravalvular regurgitation, the company stated. Meanwhile, a five year study of patients treated with the first generation SAPIEN device showed that the patients had equivalent outcomes to traditional open-heart surgery, and no structural valve deterioration requiring intervention, the company stated. ANALYST REACTION: Edwards' Sapien 3 data was impressive, as the device showed one of the lowest stroke and mortality rates of any major TAVR study so far, Bernstein analyst Derrick Sung wrote in a note to investors earlier today. Data presented by Edwards and other companies at the American College of Cardiology, or ACC, conference this weekend caused investors and the medical community to become more optimistic about the potential for TAVR devices to replace surgical valves, Sung stated. The analyst wrote that he continues to believe that investors are underestimating the potential size of the TAVR market. Also upbeat on Edwards' data was Wells Fargo, which wrote that the data exceeded high expectations and could pressure the FDA to approve Sapien 3 for intermediate risk patients earlier than Edwards' guidance of late 2016. WHAT'S NOTABLE: Analysts were also upbeat on data reported by other companies at the ACC conference. Medtronic's (MDT) data suggested that its CoreValve Evolut-R product may be as effective as Edwards' Sapien 3, Bernstein's Sung stated. The FDA appears to have allowed Boston Scientific's (BSX) left atrial appendage closure, Watchman, to be provided to more patients than expected, research firm Stifel believes. Meanwhile, St. Jude's (STJ) CardioMEMS device yielded "impressive" mortality data, the firm added. Stifel kept Buy ratings on both Medtronic and St. Jude. PRICE ACTION: In early afternoon trading, Edwards Lifesciences climbed 9% to $147.64, Boston Scientific advanced 4% to $17.27, St. Jude added 2% to $67.55, and Medtronic rose 1.3% to $77.50.
09:22 EDTBSXOn The Fly: Pre-market Movers
Subscribe for More Information
07:25 EDTBSXBoston Scientific Watchman indication 'very favorable,' says Bernstein
Subscribe for More Information
March 13, 2015
18:57 EDTBSXBoston Scientific receives FDA approval for WATCHMAN device
Subscribe for More Information
14:25 EDTKORSMichael Kors volatility at low end of historic range
Subscribe for More Information
07:49 EDTTTWOVideo game hardware sales up 10% in February, software up 7%, Game Informer says
Subscribe for More Information
05:42 EDTTTWOFebruary video game software sales rose 7%, says Piper Jaffray
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use